Associate Chief Physician PI, Shanghai Key Laboratory of Gynecologic Oncology, Associate Researcher Specialties: Specializes in the diagnosis, treatment, and prevention (including familial prevention) of familial, hereditary, and various complex benign and malignant gynecological tumors (including drug-resistant and recurrent cases), including: ovarian cancer, endometrial cancer, cervical cancer, cysts and atypical hyperplasia originating from the ovary/fallopian tube, endometrial hyperplasia/polyps (recurrent), cervical precancerous lesions (human papillomavirus genome integration, vertical transmission), gestational trophoblastic disease, breast-ovarian cancer syndrome (involving single or multiple organs), hereditary nonpolyposis colorectal cancer (Lynch syndrome, involving the uterus, ovaries, and breast), as well as targeted therapy, immune cell therapy, and gene therapy. Research Achievements: Has undertaken multiple projects including sub-topics of the National Key R&D Program, General Projects of the National Natural Science Foundation of China, Shanghai Municipal Science and Technology Commission Technical Support Projects, and Key Industry-University-Research-Medical Research Projects. Has participated in several major national projects such as the "Climbing Program," "863 Program," and "11th Five-Year Support Program." Has published more than 20 papers in journals such as J Proteome Res, Cancer Lett, Oncotarget, J Trans Med, Clin Trans Med, and Int J Cancer, with 8 patented technology transformation achievements (products). Serves as an ad hoc reviewer for Chinese Journal of Cancer Biotherapy, J Trans Med, Oncotarget, Cancer, Cancer Lett, Cell Mol Immunol, JOG, JOGR, and IEEE-JBHI. Awarded the title of Shanghai Youth Science and Technology Rising Star in 2010, recipient of the 2018 Yangpu District "3310" Class A Program, and received the First Prize for Outstanding Industry-University-Research Cooperation Project of Shanghai in 2022. Research Direction: Since 2003, has long been engaged in clinical and basic research related to obstetrics and gynecology, including cancer, stem cells, and molecular genetics. Actively explores new "Industry-University-Research-Medical" cooperation models and has obtained invention patents for synchronous typing and quantitative detection of multiple subtypes of human papillomavirus (HPV) by PCR, integrated HPV PCR detection methods, and a series of pathological molecular typing detection technologies for cervical precancerous lesions. Since 2006, has conducted in-depth research on population-based prevention, early diagnosis, and screening of ovarian cancer. Completed a two-year postdoctoral training in the Department of Obstetrics and Gynecology at the University of Pennsylvania from 2015 to 2017, focusing on CAR-T development. Since then, has been continuously engaged in targeted, immune, cellular, and gene therapy research for ovarian cancer, endometrial cancer, and cervical cancer, and actively promotes the clinical practice of genetically engineered immune cell therapy using umbilical cord blood-derived T and NK cells in China.